Hydrochloric Acid → HCID 86679008, compound
Reaction equation
C[Mg]Br.[CH2:4]1COCC1.[NH2:9][C:10]1[C:11]2[C:37]([CH3:44])([C:38]([NH:40][CH:41]3[CH2:43][CH2:42]3)=[O:39])[C:36](=[O:45])[NH:35][C:12]=2[N:13]=[C:14]([C:16]2[C:24]3[C:19](=[N:20][C:21](Cl)=[CH:22][CH:23]=3)[N:18]([CH2:26][CH2:27][C:28]([F:34])([F:33])[C:29]([F:32])([F:31])[F:30])[N:17]=2)[N:15]=1.Cl>CN1C(=O)CCC1>[NH2:9][C:10]1[C:11]2[C:37]([CH3:44])([C:38]([NH:40][CH:41]3[CH2:43][CH2:42]3)=[O:39])[C:36](=[O:45])[NH:35][C:12]=2[N:13]=[C:14]([C:16]2[C:24]3[C:19](=[N:20][C:21]([CH3:4])=[CH:22][CH:23]=3)[N:18]([CH2:26][CH2:27][C:28]([F:34])([F:33])[C:29]([F:32])([F:31])[F:30])[N:17]=2)[N:15]=1Participants
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
Methylmagnesium bromide (0.42 ml, 0.584 mmol, 1.4 M in THF) was added to a THF (1.2 ml) and NMP (0.3 ml) solution containing 4-amino-2-(6-chloro-1-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-N-cyclopropyl-5-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, as described in Example 176, (53 mg, 0.097 mmol) and iron(111) acetylacetonate (34.4 mg, 0.097 mmol). After stirring at rt for 30 min. the reaction mixture was adjusted to pH 7 with 1N HCl at 0° C. The reaction mixture was filtered through a plug of Celite™ (diatomaceous earth) and the filtrate was washed with ethyl acetate (30 mL). The combined organic fractions were evaporated under reduced pressure. The residue was purified by reverse phase HPLC to afford the indicated product. Chiral separation using SFC on a Chiralcel OJ column provided both enantiomers of the title compound. 1H NMR (500 MHz, CD3COCD3): δ 0.58 (m, 2H); 0.73 (M, 2H); 1.78 (s, 3H); 2.68 (s, 3H), 2.80 (m, 1H); 3.10 (m, 2H); 4.94 (t, J=7.1 Hz, 2H); 7.26 (d, J=8.2 Hz, 2H); 7.52 (br, 1H); 7.79 (br, 1H); 8.74 (d, J=8.2 Hz, 1H). m/z=525.17 (M+H).
Workup
- filtrationThe reaction mixture was filtered through a plug of Celite™ (diatomaceous earth)
- washthe filtrate was washed with ethyl acetate (30 mL)
- customThe combined organic fractions were evaporated under reduced pressure
- customThe residue was purified by reverse phase HPLC
- customto afford the indicated product
- customChiral separation
Sources & evidence
- ORD record
- ord-f97774f89a744534a6237a4fe927c3e0
- Source dataset
- uspto-grants-2016_06
- Patent number
- US09365574B2
Reaction notes
Loading…